|
1
|
Wang H, Zhou M, Shi B, et al:
Identification of an exon 4-deletion variant of epidermal growth
factor receptor with increased metastasis-promoting capacity.
Neoplasia. 13:461–471. 2011.PubMed/NCBI
|
|
2
|
Xue C, Wyckoff J, Liang F, et al:
Epidermal growth factor receptor overexpression results in
increased tumor cell motility in vivo coordinately with enhanced
intravasation and metastasis. Cancer Res. 66:192–197. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pandiella A, Lehvaslaiho H, Magni M,
Alitalo K and Meldolesi J: Activation of an EGFR/neu chimeric
receptor: early intracellular signals and cell proliferation
responses. Oncogene. 4:1299–1305. 1989.PubMed/NCBI
|
|
4
|
Liang K, Ang KK, Milas L, Hunter N and Fan
Z: The epidermal growth factor receptor mediates radioresistance.
Int J Radiat Oncol Biol Phys. 57:246–254. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ho R, Minturn JE, Hishiki T, et al:
Proliferation of human neuroblastomas mediated by the epidermal
growth factor receptor. Cancer Res. 65:9868–9875. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Modjtahedi H and Essapen S: Epidermal
growth factor receptor inhibitors in cancer treatment: advances,
challenges and opportunities. Anticancer Drugs. 20:851–855. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engelman JA and Cantley LC: A sweet new
role for EGFR in cancer. Cancer Cell. 13:375–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chaffanet M, Chauvin C, Laine M, et al:
EGF receptor amplification and expression in human brain tumours.
Eur J Cancer. 28:11–17. 1992. View Article : Google Scholar
|
|
9
|
Nishikawa R, Ji XD, Harmon RC, et al: A
mutant epidermal growth factor receptor common in human glioma
confers enhanced tumorigenicity. Proc Natl Acad Sci USA.
91:7727–7731. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang P, Steck PA and Yung WK: The
autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol.
35:303–314. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hwang MK, Bode AM, Byun S, et al:
Cocarcinogenic effect of capsaicin involves activation of EGFR
signaling but not TRPV1. Cancer Res. 70:6859–6869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Newman DJ, Cragg GM and Snader KM: Natural
products as sources of new drugs over the period 1981–2002. J Nat
Prod. 66:1022–1037. 2003.PubMed/NCBI
|
|
13
|
Graham JG, Quinn ML, Fabricant DS and
Farnsworth NR: Plants used against cancer - an extension of the
work of Jonathan Hartwell. J Ethnopharmacol. 73:347–377. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Samuelsen AB: The traditional uses,
chemical constituents and biological activities of Plantago
major L. A review. J Ethnopharmacol. 71:1–21. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Galvez M, Martin-Cordero C, Lopez-Lazaro
M, Cortes F and Ayuso MJ: Cytotoxic effect of Plantago spp.
on cancer cell lines. J Ethnopharmacol. 88:125–130. 2003.
|
|
16
|
Papiez MA: The influence of hollyhock
extract administration on testicular function in rats. J Mol
Histol. 35:733–740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang NJ, Lee KW, Rogozin EA, et al: Equol,
a metabolite of the soybean isoflavone daidzein, inhibits
neoplastic cell transformation by targeting the
MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem.
282:32856–32866. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ehmann LM, Heinemann V and Wollenberg A:
New tyrosine kinase and EGFR inhibitors in cancer therapy: Cardiac
and skin toxicity as relevant side effects. Part B: skin. Internist
(Berl). 52:1359–1364. 2011.(In German).
|
|
19
|
Cheung CW, Gibbons N, Johnson DW and Nicol
DL: Silibinin - a promising new treatment for cancer. Anticancer
Agents Med Chem. 10:186–195. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fahey JW, Haristoy X, Dolan PM, et al:
Sulforaphane inhibits extracellular, intracellular, and
antibiotic-resistant strains of Helicobacter pylori and
prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci
USA. 99:7610–7615. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yanaka A, Fahey JW, Fukumoto A, et al:
Dietary sulforaphane-rich broccoli sprouts reduce colonization and
attenuate gastritis in Helicobacter pylori-infected mice and
humans. Cancer Prev Res (Phila). 2:353–360. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Butler MS: The role of natural product
chemistry in drug discovery. J Nat Prod. 67:2141–2153. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Koehn FE and Carter GT: The evolving role
of natural products in drug discovery. Nat Rev Drug Discov.
4:206–220. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shokrzadeh M, Azadbakht M, Ahangar N,
Hashemi A and Saeedi Saravi SS: Cytotoxicity of hydro-alcoholic
extracts of Cucurbitapepo and Solanum nigrum on HepG2 and CT26
cancer cell lines. Pharmacogn Mag. 6:176–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Etkin NL: A Hausa herbal pharmacopoeia:
biomedical evaluation of commonly used plant medicines. J
Ethnopharmacol. 4:75–98. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Misumi N, Hiraike M, Nawata F, et al:
[Protective effects of d-chlorpheniramine maleate pre-treatment
against acute side effects of Irinotecan(CPT- 11)]. Gan To Kagaku
Ryoho. 38:1149–1153. 2011.(In Japanese).
|
|
27
|
Sun X, Zhang J, Gupta R, Macgibbon AK,
Kuhn-Sherlock B and Krissansen GW: Dairy milk fat augments
paclitaxel therapy to suppress tumour metastasis in mice, and
protects against the side-effects of chemotherapy. Clin Exp
Metastasis. 28:675–688. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang DF, Shang JY and Yu QH: Analgesic and
anti-inflammatory effects of the flower of Althaea rosea (L.) Cav.
Zhongguo Zhong Yao Za Zhi. 14(46–48): 641989.(In Chinese).
|
|
29
|
Furuse J: Growth factors as therapeutic
targets in HCC. Crit Rev Oncol Hematol. 67:8–15. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Khalil MY, Grandis JR and Shin DM:
Targeting epidermal growth factor receptor: novel therapeutics in
the management of cancer. Expert Rev Anticancer Ther. 3:367–380.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mimeault M, Pommery N and Henichart JP:
New advances on prostate carcinogenesis and therapies: involvement
of EGF-EGFR transduction system. Growth Factors. 21:1–14. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Amstad PA, Liu H, Ichimiya M, Berezesky IK
and Trump BF: Manganese superoxide dismutase expression inhibits
soft agar growth in JB6 clone41 mouse epidermal cells.
Carcinogenesis. 18:479–484. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kang NJ, Lee KW, Kwon JY, et al:
Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse
epidermal cells by blocking Raf/mitogen-activated protein kinase
kinase/extracellular signal-regulated kinase signaling. Cancer Prev
Res (Phila). 1:522–531. 2008. View Article : Google Scholar
|
|
34
|
Dong Z and Bode AM: Proceedings -
targeting carcinogenesis: transduction, transcription, translation.
Mol Carcinog. 45:353–354. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nguyen-Ba G and Vasseur P: Epigenetic
events during the process of cell transformation induced by
carcinogens (Review). Oncol Rep. 6:925–932. 1999.PubMed/NCBI
|
|
36
|
Lee KW, Kang NJ, Rogozin EA, et al:
Myricetin is a novel natural inhibitor of neoplastic cell
transformation and MEK1. Carcinogenesis. 28:1918–1927. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gschwind A, Zwick E, Prenzel N, Leserer M
and Ullrich A: Cell communication networks: epidermal growth factor
receptor transactivation as the paradigm for interreceptor signal
transmission. Oncogene. 20:1594–1600. 2001. View Article : Google Scholar
|
|
39
|
Fichera A, Little N, Jagadeeswaran S, et
al: Epidermal growth factor receptor signaling is required for
microadenoma formation in the mouse azoxymethane model of colonic
carcinogenesis. Cancer Res. 67:827–835. 2007. View Article : Google Scholar
|
|
40
|
Wakeling AE, Guy SP, Woodburn JR, et al:
ZD1839 (Iressa): an orally active inhibitor of epidermal growth
factor signaling with potential for cancer therapy. Cancer Res.
62:5749–5754. 2002.PubMed/NCBI
|
